window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 20, 2026

  • News
  • About Us
Contact Us

Er-Kim

  • Biologics & Biosimilars,Global health,Market Access & Commercialization,Pharmaceuticals and therapeutics,Rare Diseases,Supply Chain & Logistics

    Er-Kim to commercialize Nulibry and Zokinvy across Central and Eastern Europe, Mediterranean and Eurasia

    Er-Kim has signed an agreement with Sentynl Therapeutics to distribute [...]

    September 29, 2025
  • Oncology,Partnerships & Funding

    Er-Kim secures exclusive oncology distribution agreement with CNX Therapeutics across Central and Eastern Europe and Türkiye

    Er-Kim has signed an exclusive distribution agreement with CNX Therapeutics [...]

    August 27, 2025
  • Drug Development,Partnerships & Funding

    Er-Kim to distribute Nerlynx in CIS and Eastern Europe to improve HER2-positive breast cancer treatment access

    May 5, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Cereno Scientific publishes first peer-reviewed data on HDAC inhibitor CS014 showing antithrombotic effects without bleeding risk
    Categories: Biotech, Clinical Development, Drug Development, European biotech, Hematology, Research & Development, Respiratory
  • SPT Labtech adds automated Twist Bioscience NGS library preparation workflows to firefly platform
    Categories: Data Management, Genomics and sequencing, Research & Development, Technology and platforms
  • Almirall to launch phase 3 LumiNE study of lebrikizumab in nummular eczema
    Categories: Clinical Trials, Dermatology, Drug Development, European biotech, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top